Innovative Medicines Initiative (IMI)- Aimed to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need, facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world's biggest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). Through the IMI programme, a €3.3 billion budget for the period 2014-2020.
Topic-specific webinars for IMI2 – Call 20, will hold during 22/01/2020 -31/01/2020